Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation

Chieh Hsi Wu, Chih Wen Chen, Ho Chih Chen, Weng Cheng Chang, Min Ji Shu, Jui Sung Hung

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The pathological mechanism of percutaneous transluminal coronary angioplasty-induced restenosis has been attributed to outgrowth of vascular smooth muscle cells. Pretreatment with antioxidants has been shown to reduce restenosis. Magnolol, an active compound of Magnolia officinalis, has exhibited approximately 1,000 times more potent antioxidant effects than alpha-tocopherol. In this study, we demonstrate, using cytometric analysis, an approximate 61% reduction of smooth muscle cells progressing to the S-phase by 0.05 mg/ml of magnolol. A BrdU incorporation assay also showed a significant reduction (73%) of DNA synthesis using 0.05 mg/ml of magnolol. The protein level of the proliferating cell nuclear antigen was suppressed by approximately 48% using 0.05 mg/ml of magnolol. This was in agreement with the promoter activity of nuclear factor-kappa B, which was also attenuated by 0.05 mg/ml of magnolol. Since receptor interacting protein and caspase-3 protein expression levels were both increased by magnolol in a dose-dependent manner, the apoptotic pathway may mediate the inhibition of cell growth. Our finding that malondialdehyde formation was significantly inhibited by 0.05 mg/ml of magnolol further supported the antioxidant effect of magnolol. These studies suggest that magnolol might be a potential pharmacological reagent in preventing balloon injury-induced restenosis.

Original languageEnglish
Pages (from-to)392-399
Number of pages8
JournalJournal of Pharmacological Sciences
Volume99
Issue number4
DOIs
Publication statusPublished - 2005
Externally publishedYes

Fingerprint

Smooth Muscle Myocytes
Cell Proliferation
Antioxidants
Magnolia
Receptor-Interacting Protein Serine-Threonine Kinases
magnolol
Coronary Balloon Angioplasty
NF-kappa B
Proliferating Cell Nuclear Antigen
alpha-Tocopherol
Bromodeoxyuridine
Malondialdehyde
S Phase
Vascular Smooth Muscle
Caspase 3
Proteins
Pharmacology
DNA
Wounds and Injuries
Growth

Keywords

  • Magnolol
  • Neointima formation
  • Percutaneous transluminal coronary angioplasty
  • Restenosis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation. / Wu, Chieh Hsi; Chen, Chih Wen; Chen, Ho Chih; Chang, Weng Cheng; Shu, Min Ji; Hung, Jui Sung.

In: Journal of Pharmacological Sciences, Vol. 99, No. 4, 2005, p. 392-399.

Research output: Contribution to journalArticle

Wu, Chieh Hsi ; Chen, Chih Wen ; Chen, Ho Chih ; Chang, Weng Cheng ; Shu, Min Ji ; Hung, Jui Sung. / Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation. In: Journal of Pharmacological Sciences. 2005 ; Vol. 99, No. 4. pp. 392-399.
@article{c0044696ea7a4d9ebfd8e2dcc7ad2c56,
title = "Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation",
abstract = "The pathological mechanism of percutaneous transluminal coronary angioplasty-induced restenosis has been attributed to outgrowth of vascular smooth muscle cells. Pretreatment with antioxidants has been shown to reduce restenosis. Magnolol, an active compound of Magnolia officinalis, has exhibited approximately 1,000 times more potent antioxidant effects than alpha-tocopherol. In this study, we demonstrate, using cytometric analysis, an approximate 61{\%} reduction of smooth muscle cells progressing to the S-phase by 0.05 mg/ml of magnolol. A BrdU incorporation assay also showed a significant reduction (73{\%}) of DNA synthesis using 0.05 mg/ml of magnolol. The protein level of the proliferating cell nuclear antigen was suppressed by approximately 48{\%} using 0.05 mg/ml of magnolol. This was in agreement with the promoter activity of nuclear factor-kappa B, which was also attenuated by 0.05 mg/ml of magnolol. Since receptor interacting protein and caspase-3 protein expression levels were both increased by magnolol in a dose-dependent manner, the apoptotic pathway may mediate the inhibition of cell growth. Our finding that malondialdehyde formation was significantly inhibited by 0.05 mg/ml of magnolol further supported the antioxidant effect of magnolol. These studies suggest that magnolol might be a potential pharmacological reagent in preventing balloon injury-induced restenosis.",
keywords = "Magnolol, Neointima formation, Percutaneous transluminal coronary angioplasty, Restenosis",
author = "Wu, {Chieh Hsi} and Chen, {Chih Wen} and Chen, {Ho Chih} and Chang, {Weng Cheng} and Shu, {Min Ji} and Hung, {Jui Sung}",
year = "2005",
doi = "10.1254/jphs.FP0050473",
language = "English",
volume = "99",
pages = "392--399",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8648",
publisher = "Japanese Pharmacological Society",
number = "4",

}

TY - JOUR

T1 - Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation

AU - Wu, Chieh Hsi

AU - Chen, Chih Wen

AU - Chen, Ho Chih

AU - Chang, Weng Cheng

AU - Shu, Min Ji

AU - Hung, Jui Sung

PY - 2005

Y1 - 2005

N2 - The pathological mechanism of percutaneous transluminal coronary angioplasty-induced restenosis has been attributed to outgrowth of vascular smooth muscle cells. Pretreatment with antioxidants has been shown to reduce restenosis. Magnolol, an active compound of Magnolia officinalis, has exhibited approximately 1,000 times more potent antioxidant effects than alpha-tocopherol. In this study, we demonstrate, using cytometric analysis, an approximate 61% reduction of smooth muscle cells progressing to the S-phase by 0.05 mg/ml of magnolol. A BrdU incorporation assay also showed a significant reduction (73%) of DNA synthesis using 0.05 mg/ml of magnolol. The protein level of the proliferating cell nuclear antigen was suppressed by approximately 48% using 0.05 mg/ml of magnolol. This was in agreement with the promoter activity of nuclear factor-kappa B, which was also attenuated by 0.05 mg/ml of magnolol. Since receptor interacting protein and caspase-3 protein expression levels were both increased by magnolol in a dose-dependent manner, the apoptotic pathway may mediate the inhibition of cell growth. Our finding that malondialdehyde formation was significantly inhibited by 0.05 mg/ml of magnolol further supported the antioxidant effect of magnolol. These studies suggest that magnolol might be a potential pharmacological reagent in preventing balloon injury-induced restenosis.

AB - The pathological mechanism of percutaneous transluminal coronary angioplasty-induced restenosis has been attributed to outgrowth of vascular smooth muscle cells. Pretreatment with antioxidants has been shown to reduce restenosis. Magnolol, an active compound of Magnolia officinalis, has exhibited approximately 1,000 times more potent antioxidant effects than alpha-tocopherol. In this study, we demonstrate, using cytometric analysis, an approximate 61% reduction of smooth muscle cells progressing to the S-phase by 0.05 mg/ml of magnolol. A BrdU incorporation assay also showed a significant reduction (73%) of DNA synthesis using 0.05 mg/ml of magnolol. The protein level of the proliferating cell nuclear antigen was suppressed by approximately 48% using 0.05 mg/ml of magnolol. This was in agreement with the promoter activity of nuclear factor-kappa B, which was also attenuated by 0.05 mg/ml of magnolol. Since receptor interacting protein and caspase-3 protein expression levels were both increased by magnolol in a dose-dependent manner, the apoptotic pathway may mediate the inhibition of cell growth. Our finding that malondialdehyde formation was significantly inhibited by 0.05 mg/ml of magnolol further supported the antioxidant effect of magnolol. These studies suggest that magnolol might be a potential pharmacological reagent in preventing balloon injury-induced restenosis.

KW - Magnolol

KW - Neointima formation

KW - Percutaneous transluminal coronary angioplasty

KW - Restenosis

UR - http://www.scopus.com/inward/record.url?scp=29144460129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144460129&partnerID=8YFLogxK

U2 - 10.1254/jphs.FP0050473

DO - 10.1254/jphs.FP0050473

M3 - Article

VL - 99

SP - 392

EP - 399

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8648

IS - 4

ER -